H1N1 News and Research

RSS
Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

WHO official rejects claims agency overhyped threat of H1N1

WHO official rejects claims agency overhyped threat of H1N1

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

Whitley urges public to get vaccinated against H1N1 influenza virus

Whitley urges public to get vaccinated against H1N1 influenza virus

New genetic evidence can improve avian influenza surveillance programs

New genetic evidence can improve avian influenza surveillance programs

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

Send Word Now to provide emergency voice and text communication services to Unity Health System's hospitals

Send Word Now to provide emergency voice and text communication services to Unity Health System's hospitals

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

ETMC Athens gears up for next flu pandemic

ETMC Athens gears up for next flu pandemic

Pediatric specialists and pharmacists may get boost from health bills

Pediatric specialists and pharmacists may get boost from health bills

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

Life Technologies to acquire AcroMetrix

Life Technologies to acquire AcroMetrix

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

Department of Health vaccinates 49,078 Pennsylvanians at 33 H1N1 flu clinics

Department of Health vaccinates 49,078 Pennsylvanians at 33 H1N1 flu clinics

American Heart Association encourages more Americans to get vaccinated against H1N1

American Heart Association encourages more Americans to get vaccinated against H1N1

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI completes validation of its GMP manufacturing facility

CVS/pharmacy and MinuteClinic urge Americans to protect themselves with H1N1 vaccine

CVS/pharmacy and MinuteClinic urge Americans to protect themselves with H1N1 vaccine

American Red Cross urges Americans to get vaccinated against H1N1 virus

American Red Cross urges Americans to get vaccinated against H1N1 virus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.